font size
Sign in


Payers Look to
Curb Spending on
Specialty Drugs

Podcast: August 18, 2014

The rising cost of specialty drugs continues to be a battleground between drugmakers, healthcare providers, and payers over the cost of innovative therapies. Express Scripts recently did a study that suggested more than $9 billion will be wasted by U.S. Health Plan sponsors in 2015 and separately added 66 exclusions to its formulary that included several newly approved and high profile drugs. We spoke to Steve Miller, chief medical officer of Express Scripts, about striking a balance between innovation and costs, how waste in the system can be addressed, and whether and when biosimilars will begin to curb rising costs.

Read More
Todays Stories
Podcast Therapeutic Vaccine for Parkinson's Disease Shows Early Promise

Kuldip Dave, director of research programs for the Michael J. Fox Foundation, discusses encouraging early-stage results for Affiris' experimental therapeutic vaccine for Parkinson's, what the results tell us, and why alpha-synuclein may be a compelling target in the fight against Parkinson’s disease.

By the numbers Pharmas Tap Academia for Drug Discovery

Non-traditional partnering deals have become the norm over the past few years as Big Pharma has shifted its resources away from internal R&D to outsourcing innovation. Such was the case over the past week as Bristol-Myers Squibb and Astellas Pharma partnered to access biopharmaceutical innovation coming out of academia and research institutes.